1. Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study 
Dr James D Chalmers, MBChB, Brian J McHugh, PhD, Catherine Doherty, PhD, Maeve P Smith, MD, Prof John R Govan, PhD, David C Kilpatrick, PhD, Adam T Hill, MD 
The Lancet Respiratory Medicine 
Volume 1, Issue 3, Pages (May 2013)
DOI: /S (13)
Copyright © 2013 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
HRCT=high-resolution CT. ABPA=allergic bronchopulmonary aspergillosis.
The Lancet Respiratory Medicine 2013 1, DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

3. Figure 2 MBL serum concentrations
Datapoints are means and bars are 95% CIs. Blood samples were obtained at recruitment (baseline), day 1 (onset of exacerbation), and day 14 (end of exacerbation), and repeated when clinically stable at least 3 months after exacerbation (stability). Increase in MBL during exacerbation was only different for the high-expressing haplotypes (p=0·01 by ANOVA). MBL=mannose-binding lectin.
The Lancet Respiratory Medicine 2013 1, DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

4. Figure 3
Long-term prognosis in patients with bronchiectasis according to MBL genotype group (A) and mean reduction in percentage predicted forced expiratory volume in 1 s (B)
Error bars in (B) show standard error of the mean; p=0·3 for comparison between groups.
The Lancet Respiratory Medicine 2013 1, DOI: ( /S (13) )
Copyright © 2013 Elsevier Ltd Terms and Conditions